- |||||||||| Vectibix (panitumumab) / Amgen
Journal: Construction and evaluation of a novel Stx2a-based immunotoxin against epidermal growth factor receptor (EGFR). (Pubmed Central) - May 3, 2025 In this study, we designed and constructed a novel IT composed of a single-chain variable fragment (scFv) derived from Panitumumab, a humanized monoclonal antibody targeting EGFR, and the Shiga toxin A subunit 2 (Stx2a), a potent cytotoxic agent...Our findings suggest that the designed IT has the potential to be a promising therapeutic agent against EGFR-expressing cancers. Further studies are warranted to evaluate its efficacy in vivo and to optimize its formulation for clinical applications.
- |||||||||| omecamtiv mecarbil (AMG 423) / Amgen, Servier
Journal: Mechanistic insights into effects of the cardiac myosin activator omecamtiv mecarbil from mechanokinetic modelling. (Pubmed Central) - May 2, 2025 These encompass a reduced difference in binding free energy between the pre- and post-power-stroke states and greatly increased activation energy for the lever arm swing during the power-stroke. Better quantitative agreement, e.g., isometric force minimally changed from the control value by OM is achieved by additional changes in model parameter values previously suggested by studies of isolated proteins.
- |||||||||| Prolia (denosumab) / Amgen
Retrospective data, Review, Journal: Effect of anti-resorptive therapy on implant failure: a systematic review and meta-analysis. (Pubmed Central) - May 2, 2025 This review was conducted to systematically assess the impact of bisphosphonates (BPs) and denosumab, used as anti-resorptive therapies, on the incidence of dental implant failure...Specifically, in patients with osteoporosis, implant failure rates were not significantly influenced by the administration of BPs before the placement of dental implants, suggesting that low-dose BP therapy may not contraindicate implant placement. Nevertheless, regular check-ups and maintenance periodontal treatment must not be neglected, and concomitant biological factors should be considered to ensure the long-term success of implant rehabilitation.
- |||||||||| Prolia (denosumab) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date: Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone (clinicaltrials.gov) - May 2, 2025 P4, N=70, Active, not recruiting, Nevertheless, regular check-ups and maintenance periodontal treatment must not be neglected, and concomitant biological factors should be considered to ensure the long-term success of implant rehabilitation. Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Apr 2026 --> Sep 2026
- |||||||||| Trial completion, Trial completion date: COVER: COVID-19 VaccinE Response in Rheumatology Patients (clinicaltrials.gov) - May 2, 2025
P4, N=841, Completed, However, IV BP combined with calcitonin yielded a more rapid and pronounced decrease. Recruiting --> Completed | Trial completion date: Sep 2024 --> May 2024
- |||||||||| Journal: Management of Adult Acute Lymphoblastic Leukemia: A Review. (Pubmed Central) - May 1, 2025
Investigators have evaluated frontline and later-line regimens with combinations of tyrosine kinase inhibitors and immunotherapies with less or no chemotherapy. Future research will evaluate CD19, CD20, and CD22 multitargeting antibodies and chimeric antigen receptor T-cell therapies, new antibody formulations, and less intensive/shorter regimens.
- |||||||||| Prolia (denosumab) / Amgen, Libtayo (cemiplimab-rwlc) / Regeneron
Journal: Exposed Necrotic Bone in a Head and Neck Cancer Patient: Report of a Diagnostic Challenge. (Pubmed Central) - May 1, 2025 The patient currently undergoes follow-up visits monthly; the combination of photobiomodulation therapy and cycles of antibiotics keeps the necrotic lesion steady, and the oncological therapy prevents the growth of the cutaneous squamous cell cancer. The current case supports the need for histological examination to resolve the diagnostic challenge of mandibular exposed necrotic bone and to differentiate among osteoradionecrosis, stage-III medication-related osteonecrosis of the jaws, and intraoral localization of cutaneous squamous cell carcinoma.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Retrospective data, Journal: Statins and Thyroid Eye Disease: A Propensity Score-Matched Retrospective Cohort Analysis. (Pubmed Central) - May 1, 2025 Secondary objectives of this study include analyzing thyroid eye disease-related outcomes, including diplopia, optic nerve surgery, optic nerve injury, strabismus, blindness, requirement for teprotumumab, color vision deficiencies, and referral to ophthalmology...Conclusion The findings from this study suggest that statin therapy may be protective against the development of thyroid eye disease and associated complications. Further randomized controlled trials are required to validate these findings and establish a therapeutic role for statins in thyroid eye disease.
- |||||||||| Prolia (denosumab) / Amgen
Clinical, Retrospective data, Review, Journal: Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of male osteoporosis: a systematic review and Bayesian network meta-analysis. (Pubmed Central) - May 1, 2025 Future treatment decisions should balance efficacy and safety, with clinical treatment tailored to the individual needs of the patient, including the site of bone loss and sensitivity to adverse events. Future research should explore combination therapies or multi-target strategies to optimize both efficacy and safety.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen, Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche
Retrospective data, Review, Journal: Efficacy and safety of Tocilizumab for thyroid eye disease: a systemic review and Meta-analysis. (Pubmed Central) - Apr 30, 2025 According to the best available evidence, TCZ appears to be an acceptable alternative for moderate to severe TED patients due to its significant efficacy, well-tolerability, and low relapse rate. Larger sample size and controlled studies are warranted to promote the position of TCZ in TED treatment.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Journal: Truncated form of human CD19 antigen as a suicide gene to control T-cell alloreactivity: ?CD19. (Pubmed Central) - Apr 30, 2025 Importantly, the administration of the anti-hCD19-hCD3 BiTE molecule in the animal model, from one hand led to the improvement of signs and symptoms of GvHD, as well as of the overall-survival of the mice, and from the other, after a drug washout, was associated with the resurge of ?CD19-T-cells without reoccurrence of GvHD. Our study provides evidence that the ?CD19 suicide gene used in combination with an anti-hCD19-hCD3 T-cell BiTE molecule could represent a valid and effective strategy to control GvHD occurring after the infusion of donor T lymphocytes.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen, methylprednisolone sodium succinate / Generic mfg.
Clinical, Retrospective data, Review, Journal, HEOR: Teprotumumab Improves Quality of Life in Thyroid Eye Disease: Meta-analysis and Matching-adjusted Indirect Comparison. (Pubmed Central) - Apr 30, 2025 Orbital pain, teprotumumab treatment, diplopia, proptosis, and male sex were significant independent predictors of overall GO-QoL (P < .05). This unique analysis demonstrated a more clinically meaningful improvement in the health-related quality of life, as measured by the GO-QoL, for TED patients with teprotumumab vs both the most recommended IVMP dosage and placebo.
- |||||||||| Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen, docetaxel / Generic mfg.
Review, Journal: Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review. (Pubmed Central) - Apr 30, 2025 However, results from the CodeBreaK 200 Phase III trial indicated that AMG 510 did not significantly improve overall survival compared to docetaxel...Ongoing research is crucial to refine treatment regimens and identify suitable patient populations. This review focuses on the development of KRAS G12C inhibitors in monotherapy and combination therapies for NSCLC, discussing major clinical trials and future research directions.
- |||||||||| Ibrance (palbociclib) / Pfizer
Journal: Spherical Manifolds Capture Drug-Induced Changes in Tumor Cell Cycle Behavior. (Pubmed Central) - Apr 29, 2025 CDK4/6 inhibitors such as palbociclib block cell cycle progression and improve outcomes for many ER+/HER2- breast cancer patients...Understanding the molecular mechanisms that allow treated tumor cells to evade arrest is critical for identifying targets of future therapies. Ultimately, we seek to further SPCA as a tool of precision medicine, targeting treatments by individual tumors, and extending this computational framework to interpret other cyclical biological processes represented by high-dimensional data.
- |||||||||| Review, Journal: Potency and Safety of KRAS G12C Inhibitors in Solid Tumors: A Systematic Review. (Pubmed Central) - Apr 29, 2025
However, Adagrasib and Sotorasib are moderately efficient in CRC clinical trials. This study confirms that patients treated with these KRAS G12C inhibitors, exclusively or combined with conventional therapies, achieve better treatment responses and modulate the progressions of these solid tumors.
- |||||||||| Prolia (denosumab) / Amgen, Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Review, Journal: Pharmacological therapy for subchondral pathologies of the knee joint (Pubmed Central) - Apr 29, 2025 In osteonecrosis and bone marrow edema of the knee joint, complementary drug therapy may be beneficial. However, the available data is not yet sufficiently robust for general treatment recommendations.
- |||||||||| Prolia (denosumab) / Amgen, Asclera (polidocanol) / Merz Pharma
Review, Journal: Sclerotherapy with polidocanol as a treatment for aneurysmal bone cyst: A systematic review. (Pubmed Central) - Apr 28, 2025 Other interventions, like absolute alcohol gel and Denosumab, showed potential but with varying outcomes. While percutaneous sclerotherapy with polidocanol has been prominently effective in managing aneurysmal bone cysts, further studies are required to identify the most effective and least invasive treatment strategies to optimize outcomes and minimize complications in clinical practice.
|